VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy-A Message from COMET, a French Unicancer Multicentric Study

• Main Authors: Jocelyn Gal (Author), Gérard Milano (Author), Patrick Brest (Author), Nathalie Ebran (Author), Julia Gilhodes (Author), Laurence Llorca (Author), Coraline Dubot (Author), Gilles Romieu (Author), Isabelle Desmoulins (Author), Etienne Brain (Author), Anthony Goncalves (Author), Jean-Marc Ferrero (Author), Paul-Henri Cottu (Author), Marc Debled (Author), Olivier Tredan (Author), Emmanuel Chamorey (Author), Marco Carlo Merlano (Author), Jérôme Lemonnier (Author), Marie-Christine E (Author), Jean-Yves Pierga (Author)
• Format: Book
• Published: MDPI AG, 2020-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The prospective multicenter COMET trial followed a cohort of 306 consecutive metastatic breast cancer patients receiving bevacizumab and paclitaxel as first-line chemotherapy. This study was intended to identify and validate reliable biomarkers to better predict bevacizumab treatment outcomes and al...